The Ultimate Guide to Women’s Sexual Health, Hormone Replacement Therapy (HRT) & Menopause

Summary of The Ultimate Guide to Women’s Sexual Health, Hormone Replacement Therapy (HRT) & Menopause

by Mel Robbins

2h 14m•March 23, 2026
Listen to Episode

Overview of The Ultimate Guide to Women’s Sexual Health, Hormone Replacement Therapy (HRT) & Menopause (Mel Robbins Podcast)

This episode features Dr. Rachel Rubin (board‑certified urologist and sexual medicine expert) explaining practical, evidence‑based information every woman needs about hormones, genitourinary health, vaginal and systemic hormone therapies, sexual function, pelvic floor issues, and common reasons women are dismissed by the medical system. The discussion focuses on genitourinary syndrome of menopause (GSM) — and similar hormone‑driven changes at any age — simple, inexpensive treatments (notably microdosed vaginal hormones), and how to advocate for better care.

Key takeaways

  • Genitourinary symptoms (dryness, burning, painful sex, urinary frequency/urgency, recurrent UTIs, leakage and reduced sexual response) are commonly hormone‑related — not “just aging” or “all in your head.”
  • GSM (genitourinary syndrome of menopause) is a broader concept: hormone changes affect the vagina, vulva, urethra and bladder at any age (including during breastfeeding, with some birth control or endocrine therapies).
  • Microdosed vaginal hormones (vaginal estrogen or vaginal DHEA) restore pH and microbiome, reduce UTIs by more than half, relieve dryness and pain, and improve urinary symptoms — with minimal systemic absorption and excellent safety data.
  • Vaginal hormone delivery options: cream (estradiol), suppository, and vaginal ring (Estring). Typical regimen examples: 1 g estradiol cream twice weekly (after initial loading as directed), ring replaced every ~3 months.
  • Vaginal treatments are inexpensive (generic cream example: ~$13/tube ≈ $7/month) and may soon be available OTC after advocacy and regulatory change. Major regulatory warnings that once appeared on hormone products were removed following advocacy (box warnings removed in 2025–2026).
  • Systemic HRT (estrogen ± progesterone) still important for hot flashes, night sweats, osteoporosis prevention, sleep and overall menopausal symptoms; historical overreaction to the 2002 WHI study led to undertreatment for decades.
  • Testosterone therapy can be transformational for women with low libido, low energy and related symptoms. There is no FDA‑approved testosterone product specifically for women in the U.S., but global consensus and clinical experience support low‑dose testosterone use for symptomatic women (usually one‑tenth typical male dose; effects in 4–6 months). Monitor and use shared decision‑making.
  • Many clinicians were never trained in sexual medicine, vaginal anatomy, or prescribing these therapies. Patients often need to lead the conversation and bring resources or guideline printouts.
  • Other common, treatable contributors to pain/sexual dysfunction include pelvic floor muscle dysfunction and clitoral adhesions (found in ~23% in Dr. Rubin’s data); pelvic floor PT, dilation and simple office procedures can help.

Topics discussed

  • What is a sexual medicine specialist vs. urologist vs. gynecologist, and gaps in training
  • Hormone basics across life stages: puberty, pregnancy, breastfeeding (genetic “mini‑menopause”), 30s testosterone decline, perimenopause chaos, surgical/medical menopause
  • Genitourinary Syndrome of Menopause (GSM) and Genitourinary Syndrome of Lactation (GSL)
  • Vaginal hormone therapies: how they work, options, dosing, costs, safety
  • Recurrent UTIs: hormonal root causes and prevention with vaginal hormones (microbiome/pH restoration)
  • Systemic HRT history (WHI controversy) and current perspectives
  • Testosterone for women: indications, dosing, expected benefits and side effects
  • Anatomy & sexuality: clitoral anatomy, clitoral adhesions, vulvar vestibule, why many women never learn this anatomy and how that harms care
  • Pelvic floor dysfunction: causes, how it causes pain/urinary symptoms, role of pelvic floor physical therapy
  • How to talk to clinicians, what to ask for, and how to build a “pit crew” of providers

Actionable recommendations (what to do next)

Quick checklist you can use now

  • If you have recurrent UTIs, painful sex, dryness, frequent urination/urgency, leakage, or changed libido: consider a hormonal cause and ask about vaginal hormone therapy.
  • Buy vaginal pH strips (available online) and check your vaginal pH — healthy vaginal pH ≤ ~4.5; higher pH suggests microbiome disruption.
  • Ask your clinician specifically about vaginal estrogen (examples: estradiol cream 1 g twice weekly; vaginal suppository; Estring ring every 3 months) or vaginal DHEA if appropriate.
  • If low libido is a primary symptom after addressing estrogen/progesterone, ask about a testosterone trial (check total testosterone first; use low dose and re‑assess at 4–6 months).
  • If you experience pelvic pain, pain with penetration, or urinary symptoms without proven infection, ask for pelvic floor physical therapy and examination for clitoral adhesions/vulvar vestibule issues.
  • Get an exam or at least a guided self‑inspection with a mirror: know your anatomy (labia majora/minora, clitoral hood/head, vestibule, urethral opening).
  • Bring printed guidance or the AUA GSM guideline (2025) to your clinician if they are unfamiliar — you may need to lead the conversation.

Suggested doctor script (short)

  • “I have [state symptoms: recurrent UTIs / painful sex / dryness / urgency / low libido]. I’ve read these are often hormone‑related. Can we evaluate for genitourinary syndrome of menopause/lactation and discuss vaginal hormone therapy or vaginal DHEA? If you’re not familiar, I have the AUA guidelines and Dr. Rubin’s patient resources I can share.”

Dosages & logistics (examples mentioned)

  • Vaginal estradiol cream: typical microdose 1 g, twice weekly (after any loading dosing your clinician may prescribe).
  • Vaginal ring (Estring): local low‑dose estrogen ring changed approximately every 3 months.
  • Vaginal DHEA: local androgen support for tissue that also needs androgens (may be used when available/appropriate).
  • Testosterone gel for women: low dose, often ~0.5 mL daily (one‑tenth male dosing) — effects commonly seen at 4–6 months; requires a clinician experienced in dosing and monitoring.
  • Cost: generic vaginal estrogen cream example ~$13/tube (about 2.5 months supply); costs vary by product/insurance.

Safety notes

  • Vaginal microdosed hormones have minimal systemic absorption; brief blips in serum estradiol may occur but generally do not produce whole‑body estrogen levels. They are considered safe for most people and can be life‑changing.
  • Shared decision‑making remains essential for anyone with complex medical history (e.g., certain cancers). Recent evidence and advocacy led to removal of prior blanket boxed warnings that contributed to decades of undertreatment.
  • Systemic HRT decisions (estrogen ± progesterone) still require individualized discussion of risks and benefits.

Notable quotes & insights

  • Dr. Rubin: “The vagina is like a plant: it needs hormones to thrive — give it what it needs and it will flourish.”
  • Dr. Rubin: “Vaginal hormones prevent urinary tract infections by more than half.”
  • Dr. Rubin: “There is no one who can’t have vaginal estrogen — it’s a shared‑decision therapy and is often the foundational treatment for genitourinary symptoms.”
  • Mel Robbins: “This is a life‑changing and maybe even a life‑saving resource that you can share for free with women in your life.”

Practical signs that you should act (who should consider evaluation)

  • Recurrent UTIs (especially repeating despite standard care)
  • Painful sex, new genital pain or burning
  • Persistent vaginal dryness or cracking/bleeding
  • Increased urinary frequency, urgency or new leakage
  • Marked decline in libido or sexual satisfaction
  • Postpartum/breastfeeding patients with vaginal/urinary symptoms
  • Anyone on hormonal medications (combined OCPs, spironolactone for acne, endocrine therapy for breast cancer) who develops genital/urinary symptoms

Where to learn more / resources mentioned

  • Dr. Rachel Rubin — rachelrubinmd.com (articles, downloadable guidance, courses)
  • American Urologic Association (AUA) guidelines on Genitourinary Syndrome of Menopause (2025)
  • International Society for the Study of Women’s Sexual Health (ISSWSH / ISWISH) — education and find‑a‑provider
  • The Menopause Society (clinical resources)
  • Documentaries referenced: Pink Pill (Paramount+), Balance (Apple TV series), M Factor / Before the Pause (PBS)
  • Patient resources and clinician courses listed on Dr. Rubin’s site and ISWISH

How to talk to your clinician (brief sample)

  • “I’ve been having [X symptoms]. I’ve read these are often hormone‑related and respond well to local vaginal estrogen/DHEA or other therapies. Can we evaluate for genitourinary syndrome and discuss a trial of vaginal hormone therapy (or referral to a pelvic floor PT/sexual medicine specialist)?”
  • If clinician resists: “If you’re not the right specialist for this, can you refer me to someone who is trained in female sexual medicine or urology/menopause care? I can bring the AUA guideline summary for reference.”

Final note (why this matters)

This episode reframes many common female symptoms as diagnosable, treatable, and often preventable. Many inexpensive, low‑risk treatments exist (vaginal estrogen/DHEA and, where appropriate, systemic HRT or low‑dose testosterone) that can dramatically improve quality of life — sexual function, urinary health, sleep, mood and the ability to participate fully in daily life. If you relate to any of the symptoms discussed, consider bringing this evidence to your clinician or seeking a clinician trained in sexual medicine or pelvic health.

If you want, use the checklist above as a one‑page printout to bring to your appointment (vaginal pH strip result, symptom list, the sample script and request to discuss AUA GSM guidelines).